Progyny, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David J. Schlanger
- Full Time Employees
- 675
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 1359 Broadway New York City NY United States of America 10018
- IPO Date
- Oct 25, 2019
- CIK
- 0001551306
- Website
- progyny.com
- Similar Companies
- Business
- Progyny, Inc. is a benefits management company specializing in fertility, family building, and women's health benefits solutions in the United States. Founded in 2008 and headquartered in New York City, Progyny offers an integrated suite of products and services that include fertility benefits management; access to a network of top fertility specialists, including reproductive endocrinologists and reproductive urologists; preconception and trying-to-conceive clinical programming and coaching; personalized surrogacy and adoption support; an integrated pharmacy benefits solution (Progyny Rx) providing discounts on fertility medications and patient care; and digital tools with 1:1 member concierge support. The company serves employers, health plans, and benefit purchasers seeking to provide comprehensive reproductive and family-building benefits. Progyny’s offerings extend from preconception through fertility treatments like intrauterine insemination and in vitro fertilization, continuing through pregnancy, postpartum care, menopause, and midlife women’s health support. Recent developments include significant growth during 2024, with the addition of 80 new clients expanding covered lives by 1.1 million. The company achieved its ninth consecutive year of revenue growth, reporting full-year 2024 revenue of $1.17 billion, up 7%, and Q4 revenue growth of 11% year-over-year. Progyny strengthened its market presence with its first-ever national health plan partnership with Cigna, expanding go-to-market reach. It launched new services in maternity, postpartum, and menopause care, which have seen strong adoption. The company continues investing in digital assets and product innovation, positioning for continued growth in 2025 with a forecasted revenue range of $1.175 billion to $1.225 billion. Progyny maintains a high client retention rate of approximately 99%, reflecting strong customer relationships and market leadership in fertility and women's health benefits. Progyny operates primarily in the U.S. market, providing solutions that address the complex needs of fertility and reproductive health through a data-driven, outcomes-focused model. The company’s family building benefit includes financial support and guidance for surrogacy and adoption, distinguishing it as a comprehensive provider that supports diverse paths to parenthood. Progyny's business segments cover fertility benefit services and pharmacy benefits, with recent expansions into broader women's health services. Its integrated approach leverages clinical expertise, technology, and personalized support to optimize clinical outcomes, cost savings, and member experience. Overall, Progyny, Inc. is recognized as a leading provider in fertility and family building benefits, serving a predominantly employer-based clientele within the healthcare benefits industry. Its strategic partnerships, enhanced service offerings, and steady financial growth underscore its role as a transformative player in the reproductive and women’s health benefits sector.
A Progyny (PGNY) Insider Sold 5,500 Shares for $137,000
New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System
Progyny, Inc. Announces Share Repurchase Program
Progyny Inc (PGNY) Stock Down 3.8% -- Now Undervalued? GF Score: 87/100
Progyny, Inc. (PGNY) Shareholder/Analyst Call Transcript
Bull of the Day: Progyny (PGNY)
Progyny, Inc. (PGNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
3 Highly Ranked Medical Stocks to Buy Now: DVA, GMED, PGNY
Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference
Progyny Q1 Earnings Call Highlights
Progyny, Inc. (PGNY) Q1 2026 Earnings Call Transcript
Progyny (PGNY) Q1 Earnings and Revenues Beat Estimates
Progyny, Inc. Announces First Quarter 2026 Results
Should Value Investors Buy Progyny (PGNY) Stock?
Progyny (PGNY) Upgraded to Buy: Here's Why
PGNY or ALHC: Which Is the Better Value Stock Right Now?
Progyny, Inc. (NASDAQ:PGNY) Receives Consensus Rating of “Moderate Buy” from Analysts
Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report
Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report
Progyny Expands Access to Fertility and Women's Health with Industry's First Fully Insured Supplemental Plan